Heritable sclerosing bone disorders: Presentation and new molecular mechanisms

Annals of the New York Academy of Sciences

Volumn 1192, Issue , 2010, Pages 269-277

  De Vernejoul, Marie Christine ^a   Kornak, Uwe ^b  

^a INSERM   (France)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Genetic; Osteocondensation; Osteopetrosis; Osteosclerosis

Indexed keywords

CARBONATE DEHYDRATASE II; CATHEPSIN K; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ALBERS SCHOENBERG DISEASE; AUTOSOMAL RECESSIVE DISORDER; BIOLOGY; BONE MARROW TRANSPLANTATION; BONE MASS; CAMURATI ENGELMANN DISEASE; CELL DIFFERENTIATION; CLINICAL FEATURE; CONFERENCE PAPER; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; HUMAN; HYPEROSTOSIS; MOLECULAR MECHANICS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPATHIC MEDICINE; OSTEOSCLEROSIS; PATHOGENESIS; SIGNAL TRANSDUCTION;

EID: 77950656058     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05244.x     Document Type: Conference Paper

References (40)

1. Maroteaux, P. & M. Lemerrer. 2002.Maladies osseuses de l'enfant. Flammarion. Paris.
2. Whyte, M.P. 2006.Primers on theMetabolicBoneDiseases and Disorders of Mineral Metabolism. Lippincott-Raven. Philadelphia.
3. Supanchart, C. & U. Kornak. 2008. Ion channels and transporters in osteoclasts. Arch. Biochem. Biophys. 473: 161-165.
4. Frattini, A. et al. 2000. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat. Genet. 25: 343-346.
5. Schinke, T. et al. 2009. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat. Med. 15: 674-681.
6. Kornak,U. et al. 2001. Loss of theClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104: 205-215.
7. Frattini, A. et al. 2003. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J. Bone Miner. Res. 18: 1740-1747.
8. Chalhoub, N. et al. 2003. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9: 399-406.
9. Villa, A. et al. 2009. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif. Tiss. Int. 84: 1-12.
10. Sobacchi, C. et al. 2007. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39: 960-962.
11. Guerrini, M.M. et al. 2008. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 83: 64-76.
12. Benichou, O.D., J.D. Laredo & M.C. de Vernejoul. 2000.Type II autosomal dominant osteopetrosis (Albers- Schonberg disease): clinical and radiological manifestations in 42 patients. Bone 26: 87-93.
13. Waguespack, S.G. et al. 2007. Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 genemutation. J. Clin. Endocrinol. Metab. 92: 771-778.
14. Cleiren, E. et al. 2001. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum. Mol. Genet. 10: 2861-2867.
15. Henriksen, K. et al. 2004.Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am. J. Pathol. 164: 1537-1545.
16. Sly, W.S. et al. 1983. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl. Acad. Sci. USA 80: 2752-2756.
17. Maroteaux,P.&M. Lamy. 1965. The malady ofToulouse- Lautrec. JAMA 191: 715-717.
18. Gelb, B.D. et al. 1996. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273: 1236-1238.
19. Janssens, K. et al. 2006. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J. Med. Genet. 43: 1-11.
20. Janssens, K. et al. 2000. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 causeCamurati-Engelmann disease.Nat.Genet. 26: 273-275.
21. Janssens, K. et al. 2003. Transforming growth factorbeta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of themutant protein. J. Biol.Chem. 278: 7718-7724.
22. Hellemans, J. et al. 2004. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat. Genet. 36: 1213-1218.
23. Lin, F. et al. 2005. MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling. Hum. Mol. Genet. 14: 437-445.
24. Krishnan, V., H.U. Bryant & O.A. Macdougald. 2006. Regulation of bone mass byWnt signaling. J. Clin. Invest. 116: 1202-1209.
25. Hamersma, H., J. Gardner & P. Beighton. 2003. The natural history of sclerosteosis. Clin. Genet. 63: 192-197.
26. Balemans,W. et al. 2002. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39: 91-97.
27. Brunkow, M.E. et al. 2001. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum.Genet. 68: 577-589.
28. Loots, G.G. et al. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15: 928-935.
29. Little, R.D. et al. 2002. A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70: 11-19.
30. Boyden, L.M. et al. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346: 1513-1521.
31. VanWesenbeeck, L. et al. 2003. Six novel missensemutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72: 763-771.
32. Viot, G. et al. 2002. Osteopathia striata cranial sclerosis: non-random X-inactivation suggestive of X-linked dominant inheritance. Am. J. Med. Genet. 107: 1-4.
33. Jenkins, Z.A. et al. 2009. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat. Genet. 41: 95-100.
34. Castori, M. et al. 2005. Pachydermoperiostosis: an update. Clin. Genet. 68: 477-486.
35. Uppal, S. et al. 2008. Mutations in 15-hydroxy prostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat. Genet. 40: 789-793.
36. Seifert, W. et al. 2009. HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing. Eur. J. Hum. Genet. 17: 1570-1576.
37. Ghosal, S.P. et al. 1988. Diaphyseal dysplasia associated with anemia. J. Pediatr. 113: 49-57.
38. Genevieve, D. et al. 2008. Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). Nat. Genet. 40: 284-286.
39. Lange, P.F. et al. 2006. ClC-7 requires Ostm1 as a betasubunit to support bone resorption and lysosomal function. Nature 440: 220-223.
40. Jilka, R.L. 2009. Inhibiting the inhibitor: a new route to bone anabolism. J. Bone Miner. Res. 24: 575-577.